Global disparities in faecal microbiota transplantation research
Scott W. Olesen, Pratik Panchal, Justin Chen, Shrish Budree, Majdi Osman
Abstract
Faecal microbiota transplantation (FMT) is recommended therapy for recurrent Clostridioides difficile infection in adult and paediatric patients 1 McDonald LC Gerding DN Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66: e1-48 Crossref PubMed Scopus (806) Google Scholar and is being explored as treatment for a growing range of microbiome-mediated diseases. 2 Allegretti JR Mullish BH Kelly C Fischer M The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet. 2019; 394: 420-431 Summary Full Text Full Text PDF PubMed Scopus (95) Google Scholar Although microbiome-based therapies could play a key role in global health, 3 Porras AM Brito IL The internationalization of human microbiome research. Curr Opin Microbiol. 2019; 50: 50-55 Crossref PubMed Scopus (10) Google Scholar , 4 Rogers GB Ward J Brown A Wesselingh SL Inclusivity and equity in human microbiome research. Lancet. 2019; 393: 728-729 Summary Full Text Full Text PDF PubMed Scopus (7) Google Scholar global FMT research remains inequitably distributed.